{"commentary":{"count":25,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":9,"podcast":9,"x_thread":7},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05002569\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"RELATIVITY-098","nct_id":"NCT05002569","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=relativity-098-nct05002569. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":"RELATIVITY-098","arms":[{"description":"Combination","label":"Arm A: Nivolumab Plus Relatlimab","type":"EXPERIMENTAL"},{"description":"Monotherapy","label":"Arm B: Nivolumab","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2025-04-02","type":"ACTUAL"},"conditions":["Melanoma"],"enrollment":{"count":1093,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Nivolumab","type":"BIOLOGICAL"},{"name":"Nivolumab + Relatlimab Fixed Dose Combination","type":"BIOLOGICAL"}],"last_update":"2026-01-08","lead_sponsor":"Bristol-Myers Squibb","official_title":"A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy With Nivolumab + Relatlimab Fixed-dose Combination Versus Nivolumab Monotherapy After Complete Resection of Stage III-IV Melanoma","overall_status":"TERMINATED","phases":["PHASE3"],"primary_completion_date":{"date":"2024-12-16","type":"ACTUAL"},"primary_outcomes":[{"measure":"Recurrence Free Survival (RFS)","timeFrame":"Approximately 27.5 Months"}],"references":[{"citation":"Long GV, Garnett-Benson C, Dolfi S, Ascierto PA, Guo J, Tarhini AA, Chandra S, Munoz-Couselo E, Del Vecchio M, de Melo AC, Callahan M, Gogas H, Dummer R, Schadendorf D, Koelblinger P, Quereux G, Thomas I, Yu JX, Fisher A, Wang B, Djidel P, Chouzy A, Semaan M, Chen B, Cheong AMY, Tawbi HA. Plain language summary of the RELATIVITY-098 study results: nivolumab plus relatlimab given after melanoma is removed by surgery. Future Oncol. 2026 Sep 22:1-10. doi: 10.1080/14796694.2026.2721180. Online ahead of print.","pmid":"42770835","type":"DERIVED"},{"citation":"Long GV, Garnett-Benson C, Dolfi S, Ascierto PA, Guo J, Tarhini AA, Chandra S, Munoz-Couselo E, Del Vecchio M, de Melo AC, Callahan M, Gogas H, Dummer R, Schadendorf D, Koelblinger P, Quereux G, Thomas I, Yu JX, Fisher A, Wang B, Djidel P, Chouzy A, Semaan M, Chen B, Cheong AMY, Tawbi HA. Adjuvant nivolumab and relatlimab in stage III/IV melanoma: the randomized phase 3 RELATIVITY-098 trial. Nat Med. 2025 Dec;31(12):4301-4309. doi: 10.1038/s41591-025-04032-8. Epub 2025 Oct 18.","pmid":"41109920","type":"DERIVED"}],"start_date":{"date":"2021-10-19","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma","url":"https://clinicaltrials.gov/study/NCT05002569"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/relativity-098-nct05002569"}